# Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

> **NCT04732845** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Benjamin Tomlinson** · enrollment: 18 (actual)

## Conditions studied

- Non Hodgkin Lymphoma
- Acute Lymphoblastic Leukemia
- Chronic Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** Fully human anti CD19 CAR-T Cell Dose
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT04732845
- **Lead sponsor:** Benjamin Tomlinson
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-26
- **Primary completion:** 2025-09-01
- **Final completion:** 2039-12-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04732845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04732845, "Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04732845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*